Newsroom

Oradell, NJ — November 13, 2025 — The Accreditation Council for Medical Affairs (ACMA) has launched a new AI-integrated Board Certified Medical Affairs Specialist (BCMAS®) program, redefining Medical Affairs training by teaching AI literacy and application to Medical Science Liaisons (MSLs) and field medical professionals.

The Accreditation Council for Medical Affairs (ACMA) has unveiled ACMAi, a groundbreaking AI-powered learning solution designed to transform professional development in the pharmaceutical and life sciences industries. Officially launched at Fierce Pharma Week 2025, ACMAi delivers adaptive, accredited, and impactful training for medical affairs, market access, and commercial teams worldwide.

Pharmacy Times sat down with a panel of experts to discuss progress toward standardization of knowledge in the field of biosimilars, with panelists including William Soliman, PhD, founder and CEO of the Accreditation Council for Medical Affairs (ACMA); Jeff Baldetti, MBA, BCBBS, vice president of product and marketing at HealthPlan Data Solutions; and Fran Gregory, PharmD, vice president of emerging therapies and biosimilars at Cardinal Health.

Biosimilars represent an important therapeutic option in modern healthcare, offering cost-effective alternatives to complex biological drugs. The educational gap among healthcare professionals poses a challenge to their widespread adoption. Medical Affairs teams in the pharmaceutical industry are at the forefront of bridging this gap

Clarivate webinar discussing how the entry of Humira (adalimumab) biosimilars into the U.S. market following Humira’s patent expiry could affect competition, pricing, and the broader healthcare landscape for biologics and biosimilar developers.

Nurses now have a clear pathway into pharmaceutical careers through the launch of the Certified Nurse Medical Affairs Professional (CNMAP™) Program, the first accredited certification helping them apply clinical skills in the biopharmaceutical industry.

CEOs from Eli Lilly, Sanofi, and Novo Nordisk, along with executives from three pharmacy benefit managers (PBMs), appeared before the Senate Committee on Health, Education, Labor and Pension (HELP) to address insulin price reform. These companies control 90% of the global insulin market. The Inflation Reduction Act (IRA) has forced them to cap insulin copays at $35 per month and cap insulin expenses for seniors at $2,000 per year through Medicare. The high cost of insulin was attributed to both PBMs and pharmaceutical companies, with senators criticizing the lack of transparency in PBM operations. Dr. William Soliman, founder and CEO of the Accreditation Council for Medical Affairs, highlighted the need for PBM reform and Congressional action to achieve results. The urgency for revolutionary changes in the prescription drug system was emphasized.

William Soliman, CEO and founder of the Accreditation Council for Medical Affairs (ACMA), is working to establish competency standards and prevent conflicts between medical affairs departments and marketing in the pharmaceutical industry. ACMA certifies and accredits medical affairs and medical science liaisons, and Soliman aims to create uniform standards for the profession to avoid future pharmaceutical scandals. He emphasizes the importance of ethics and appropriate reporting structures within medical affairs, separating it from commercial influences

In this episode, Dr. Soliman, CEO of the Accreditation Council for Medical Affairs (ACMA), about his background, the influence of his father, and the role of the pharmaceutical industry. Growing up in Jersey City, Will was encouraged by his parents to pursue a career in STEM, leading him to major in biochemistry in college. He discusses the impact of 9/11 on immigration policies and scientific output, as well as his early career as a pharmaceutical sales rep before transitioning to a medical science liaison role.

Oprah Winfrey is releasing a new documentary called the Color of Care which highlights racial equality gaps in healthcare especially highlighted during the Covid19 pandemic. See Dr Soliman quoted and featured in this article published by Forbes regarding the importance of the work we are doing at the Accreditation Council for Medical Affairs (ACMA) around the establishment of standards for MSL and Medical affairs professionals as they play a very important role in educating the healthcare provider community.

Check out our founder and CEO Dr. William Soliman /Accreditation Council for Medical Affairs (ACMA) this weekend on iHeart Radio's A Moment of Xen w/t Xen Sams in My Healthy Minutes segment sponsored by Revere Securities where he'll discuss the ongoing opioid crisis in America, how psychedelics and cannabis are potentially used to treat addictions, mental and neurological disorders, and the priceless education the Accreditation Council for Medical Affairs (ACMA) is providing the pharmaceutical industry.

During the Reuters Event, there will be an industry-focused conversation on key topics leading pharma in 2022. This event is held to provide content that is driven by experts in their fields: marketing, commercial, data & analytics, patient engagement, patient advocacy, medical affairs, market access, RWE and clinical. As a Gold Sponsor and media partner, the event will offer continuing medical education/continuing education (CME/CE) credits to attendees.